Loading...
•
Mar 31, 2023
Castle Biosciences Q1 2023 Earnings Report
Achieved revenue growth and delivered strong test report volume.
Key Takeaways
Castle Biosciences reported a strong start to 2023 with a 57% increase in revenue compared to Q1 2022, driven by significant test report volume growth. The company reaffirmed its full-year 2023 revenue guidance of $170-180 million.
Revenues increased by 57% to $42.0 million compared to $26.9 million in the same period in 2022.
Total test reports delivered increased by 73% to 14,916 compared to 8,627 in the same period of 2022.
Gross margin was 70.5%, and adjusted gross margin was 76.5%.
The company reaffirms its previously provided 2023 total revenue guidance of $170-180 million.
Forward Guidance
The Company reaffirms its previously provided 2023 total revenue guidance of $170-180 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...